Clinical Trial Update: A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial to assess safety and tolerability of multiple doses of ALN-ANG3 in healthy adults, including individuals with hyperlipidemia; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• ALN-ANG3

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Healthy Volunteers With Hyperlipidemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING